In syngeneic mouse tumor models, systemic treatment with CD39-specific ASO resulted in potent knockdown of CD39 expression e.g. in Treg, tumor-associated macrophages and myeloid- derived suppressor cells and in a reduction of the frequency of intratumoral Treg. The gene discussed is ENTPD1; the disease is neoplasm.